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Abstract  
Purpose: 
Germline polymorphisms may affect chemotherapy efficacy and toxicity. We examined the 
effect of polymorphisms in drug metabolism and DNA repair genes on pathological response 
rates, survival, and toxicity for patients randomised to surgery alone or perioperative ECF 
chemotherapy in the MRC MAGIC trial. 
Experimental design: 
DNA was extracted from non-tumor resection FFPE blocks. ERCC1, ERCC2, XRCC1, 
DYPD, and OPRT SNPs were evaluated using Sequenom, GSTP1, GSTT1 deletion and 
TYMS (TS) 5’ 2R/3R using multiplex PCR. Post PCR amplification TS 2R/3R and GSTT1 
samples underwent gel electrophoresis. 
Results: 
Polymorphism data was available for 289/456 (63.4%) operated patients.  No polymorphism 
was statistically significantly associated with pathological response to chemotherapy.  
Median overall survival (OS) for patients treated with surgery alone with any TS genotype 
was not different (1.76 years  2R/2R, 1.68 years 2R/3R,  2.09 years 3R/3R).  Median OS for 
patients with a TS 2R/2R genotype treated with chemotherapy was not reached, whereas 
median OS for 2R/3R and 3R/3R patients were 1.44 and 1.60 years respectively (log rank p 
value 0.0053).    The p value for the interaction between treatment arm and genotype (3R/3R 
and 3R/2R vs 2R/2R) was 0.029.   No polymorphism was statistically significantly associated 
with chemotherapy toxicity. 
Conclusions:    
In MAGIC, patients with a TS 2R/2R genotype appeared to derive a larger benefit from 
perioperative ECF chemotherapy than patients with 3R containing genotypes.   Further 
exploration of this potential predictive biomarker in this patient population is warranted. 
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Statement of translational relevance 
 
Neoadjuvant or perioperative cisplatin and 5-fluorouracil based chemotherapy plus surgery 
is one standard of care for patients with resectable gastroesophageal cancer.   However, 
chemotherapy benefits only a small proportion of patients, and validated biomarkers 
predictive of response or toxicity have been elusive.    We analysed the effect of multiple 
germline polymorphisms putatively associated with response or toxicity to chemotherapy in 
patients treated with chemotherapy plus surgery or surgery alone in the UK Medical 
Research Council MAGIC Trial.   One polymorphism in thymidylate synthase (TS), a 2R/2R 
tandem repeat, was significantly associated with overall survival in patients treated with 
chemotherapy, but not in patients treated with surgery alone.   These findings suggest that 
neoadjuvant chemotherapy for patients with operable gastroesophageal cancer could be 
personalized based on germline polymorphism status.  
 
Statement of significance: 
We demonstrate in a randomised trial with a chemotherapy control arm that the presence of 
the thymidylate synthase 2R/2R genotype is associated with significantly improved overall 
survival for patients with operable gastroesophageal cancer treated with fluoropyrimidine 
based chemotherapy plus surgery.   Further validation of this potential predictive biomarker 
for chemotherapy efficacy may be appropriate.   
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INTRODUCTION 
 
Gastric and oesophageal  cancers  are the third and sixth most common causes of cancer 
death annually worldwide.(1)   Neoadjuvant or perioperative chemotherapy is one standard 
treatment for patients with operable gastric or gastroesophageal adenocarcinoma prior to 
surgical resection.(2-5)     This approach is associated with a modest (6-13%) absolute 
overall survival advantage in terms of overall survival compared to surgery alone but also 
with chemotherapy related toxicities such as nausea and vomiting, and neutropenia.     
Furthermore, following multimodality therapy half of resected patients develop incurable, 
metastatic cancer and therefore do not benefit from neoadjuvant chemotherapy.(2,4)     
Better selection of patients for preoperative chemotherapy might avoid needless toxicity, 
however currently gastroesophageal cancer patients who are treated with neoadjuvant 
chemotherapy are selected for treatment based on radiological staging alone as there are no 
currently validated predictive biomarkers for chemotherapy.   
 
Germline polymorphisms in genes associated with chemotherapy and drug metabolism have 
been validated as predictors of survival and toxicity outcomes across several tumour types 
including colorectal and breast cancer.(6-8)   Although similar studies have examined the 
effects of polymorphisms in germline genes relating to chemotherapy metabolism in 
gastroesophageal cancer, most of these have been retrospective, and all lack an untreated 
control group.(9-11)    The UK MRC MAGIC trial was an open label, multicentre, phase III 
randomised trial comparing six cycles of perioperative ECF (epirubicin, cisplatin and infused 
5-fluorouracil) chemotherapy (3 cycles pre- and 3 cycles post- resection) plus surgery to 
surgery alone in patients with resectable gastroesophageal cancer.(2)  Patients treated with 
perioperative chemotherapy had improved overall survival (OS) compared to patients treated 
with surgery alone [5 year OS 36% vs 23%, HR 0.75, (95% CI 0.60-0.93) p=0.009].   As a 
result, perioperative ECF chemotherapy became one standard treatment regimen for 
patients with resectable gastroesophageal adenocarcinoma.  We hypothesised that selected 
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germline polymorphisms would be associated with pathological response to chemotherapy, 
overall survival or chemotherapy related toxicity in the MAGIC trial, and herein present the 
results of this analysis.   
 
Methods 
Hematoxylin and eosin (H&E) stained tissue sections from resection specimens were 
reviewed by a histopathologist (AW).   DNA was extracted from non-malignant tissue. Five 
sections (10 mm thick) were cut and deparaffinised using a standard protocol, and the area 
of interest was dissected using a sterile scalpel blade.  Genomic DNA was extracted using 
the QIAmp DNA Micro Kit and QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany), 
following the manufacturer’s instructions.  After dewaxing and rehydrating the slides, tissue 
was microdissected and placed into a 1.5-mL Eppendorf tube with buffer ATL and proteinase 
K for digestion (Qiagen). DNA was eluted in buffer ATE (Qiagen) with an elution volume of 
60 mL.  Quality control of the DNA was performed on the basis of 260:230 and 260:280 ratio 
values and visual inspection of the wavelength spectral pattern provided by the NanoDrop 
spectrophotometer (Thermo Scientific, Wilmington, DE). A 260:230 ratio of approximately 
2.0, together with a 260:280 ratio of approximately 1.8 and the presence of a peak at 260 nm 
with a steep decrease toward 280 nm in the wavelength spectrum was considered 
sufficiently good quality DNA. 
Slides from all cases were reviewed and pathological response in tumour graded using the 
Mandard tumour regression grading (TRG) system.(12) 
Genotype Analysis 
Ten polymorphisms were selected based on a review of the literature and expected 
interaction with epirubicin, cisplatin and 5 fluorouracil chemotherapy.   These are listed in 
Table 1.    For detailed description of genotype analysis methodology please see 
supplementary methods.   
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Statistical methods 
OS was calculated from surgery to death from any cause or last date of follow up.  Date of 
surgery was selected as the baseline for biomarker analysis to reduce potential bias as only 
patients with a surgical specimen were available for inclusion.  Analyses were performed 
within treatment arms due to the differences in timing of surgery, to further reduce potential 
bias in the estimates of effects.  Date of surgery could not be confirmed for nine patients in 
the chemotherapy plus surgery arm and these patients were excluded from the survival 
analyses.   Differences in OS by polymorphism status were assessed using the Kaplan 
Meier method and compared using Cox regression.  To mitigate multiplicity a p-value of 
<0.01 was considered significant when testing for associations of genotypes with survival 
and toxicity, and <0.05 when testing interactions    Multiple imputation was performed to 
account for missing polymorphism data.  OS results were adjusted for possible confounders 
of age, subtype, gender, site of primary, WHO, nodal status). 
Proportions of patients with good pathological response (TRG 1-2) compared with poor 
pathological response (TRG 3-5) were compared for each genotype using the Fisher’s exact 
test.   Proportions of patients with toxicities according to genotype were compared using 
Pearson chi-squared test or Fisher’s exact test where appropriate. 
As TS 2R/2R genotype is the polymorphism of interest and is present in approximately 30% 
of patients, with median OS of 18 months in control (2R/3R + 3R/3R), power of 80%, 5% two 
sided significance level, to detect a HR of 0.5 would require 85 events. Alternatively as with 
the same assumptions as above with 70% power 67 events would be required.   With 
respect to pathological response rate in TS genotyped patients, in order to detect a doubling 
in response rates from 15% to 30%, 206 patients would be required to achieve 70% power.  
This is based on based on a pathological response rate of 15% in the 3R group, which 
accounts for 70% of patients, and 30% in the 2R/2R group (which contains 30% of patients). 
Due to the trial design and retrospective nature of these analyses, all results can only be 
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seem as hypothesis generating and suggestive of future work, with significance levels set to 
limit the possibility of a type II error. 
All analyses were conducted using Stata version 14.    The MAGIC protocol was approved 
by the relevant ethics committees, and patients gave written informed consent for 
participation in the trial.  The translational MAGIC protocol (TransMAGIC) received separate 
national ethics approval (11/LO/0566).  
Results 
Polymorphism data was available for 289/456 (63.4%) patients who underwent surgery in 
the MAGIC trial.   There was no difference in distribution of sex, performance status, site of 
tumour, age or treatment arm between patients with and without polymorphism data, 
however patients without polymorphism data were more likely to undergo a palliative 
resection in the view of the operating surgeon (Supplementary Table 1).      This resulted in a 
borderline difference in survival between patients who had polymorphism data available and 
those who did not, which was more pronounced in the surgery only arm (Supplementary 
Figure 1).    
Discordance in size based polymorphism assessment 
We found that on duplicate runs that size based polymorphism assessment that discordance 
occurred at a rate of 32.7% and 4.2% for GSTT1 and TYMS (TS) respectively.(13)     Due to 
the high rate of discordance in GSTT1 results for this polymorphism was not analysed 
further.   
Genotype frequency 
The frequency of each polymorphism genotype is described in Table 2. Genotype frequency 
was consistent with previously published data and all were in Hardy-Weinberg equilibrium 
with the exception of DPYD rs1801159.   
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Genotype and pathological response to chemotherapy 
The association between each polymorphism and pathological response to chemotherapy in 
chemotherapy treated patients is described in Table 3.    No polymorphism was statistically 
significantly associated with pathological response to chemotherapy.  
Genotype and overall survival 
Median overall survival for patients treated with surgery alone who had TS 2R/2R genotype 
was 1.76 years, compared to 1.68 years for 2R/3R and 2.09 years for 3R/3R (Table 4, 
Figure 1).  These differences were not statistically significant.    In contrast, median overall 
survival for patients with a TS 2R/2R genotype treated with chemotherapy was not reached, 
whereas survival for 2R/3R and 3R/3R were 1.44 and 1.60 years respectively (log rank p 
value 0.0053).      When all 3R genotypes were combined median overall survival was 1.44 
years for chemotherapy treated patients vs not reached for 2R/2R genotype (HR 2.4, 
p=0.003).     The effect of TS genotype on overall survival in chemotherapy treated patients 
remained statistically significant when adjusted for the potential confounders of age, 
subtype, gender, site of primary, WHO, nodal status) (Table 4).  The p value for the 
interaction between treatment arm and TS genotype (3R/3R and 3R/2R vs 2R/2R) was 
0.029 (with a HR of 0.46).  
In order to assess the effect of a 4.2% discrepancy in TS genotype status assessment we 
performed 10000 simulations, randomly changing 4.2% of results.   From these 10000 
simulations, the  2.5 to 97.5 percentiles of the HR for the interaction between treatment arm 
and TS genotype (3R/3R and 3R/2R vs 2R/2R) was 0.37 – 0.60, compared to the estimate 
from the original data of 0.46. 
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Patients with the (AG) genotype of DPYD rs1801159 Ile543Val had numerically shorter 
survival compared to the AA genotype in the surgery alone arm of the trial, this difference 
was statistically significant (HR 1.75, p=0.008).    There was no evidence of an interaction 
between treatment arm and DPYD status.    Results were similar when multiple imputation 
was performed for missing data.  
No other genotype was statistically significantly associated with overall survival (see 
Supplementary Tables 2 A-F).   
Genotype and chemotherapy related toxicity 
The presence of grade 3 or greater toxicity and association with polymorphism status are 
detailed in Supplementary Table 1 .   DPYD2A  IVS14+1G>A GA variant was associated 
with a non-statistically significant trend towards increased rates of ≥ Grade 3 diarrhoea 
(p=0.039), however only one patient was detected with this variant.   No other polymorphism 
demonstrated a statistically significant relationship with chemotherapy related toxicity.   
The mean number of cycles of chemotherapy received for most polymorphisms was five 
(Supplementary Table 3), with the exception of ERCC1 rs3212986 (GT+TT) variant who had 
a mean of four cycles (Kruskal-Wallis equality-of-populations rank test p= 0.0425).    
 
Discussion  
Our study is the first to evaluate the association between germline polymorphisms and 
pathological response,  overall survival, and chemotherapy related toxicity for patients with 
operable gastroesophageal cancer in a randomised trial with a control group.     We found 
that patients who have a 2R/2R thymidylate synthase genotype who were treated with 
perioperative ECF chemotherapy had statistically superior overall survival compared to 
those who had a 2R/3R or 3R/3R genotype.   This difference was not apparent in patients 
who were treated with surgery alone, and a significant interaction between TS genotype 
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status and treatment arm was noted   Additionally, in our study, patients with a TS 2R2R 
genotype had a non-statistically significant higher rate of good pathological response (TRG 
1-2) at 24% compared to 3R allele containing patients.   These findings are important as if 
validated pharmacogenomic genotyping could be used in future to select patients who are 
more likely to benefit from perioperative chemotherapy. 
Thymidylate synthase (TS) acts to produce thymidylate which is an essential precursor for 
DNA synthesis.   The activity of TS is blocked by 5-fluorodeoxyuridylate (5FdUMP), the 
active metabolite of 5-FU and it is via this mechanism that 5-FU exerts cytotoxicity.   The 
human thymidylate synthase gene is polymorphic through the presence of either double (2R) 
or triplet (3R) 28 base tandem repeats which are sited upstream of the TS translational start 
site. [14]   These repeats control the transcription and translation of the TS gene; individuals 
with 3R tandem repeats have higher levels of TS expression in tissue and consequently 
lower rates of response to fluoropyrimidine chemotherapy.[15]   Our findings are in keeping 
with this biology.    Several other series have reported comparable improvements in 
response rates overall survival similar results in gastric cancer patients with the favourable 
2R genotype treated with fluoropyrimidine 5-FU based chemotherapy, however none of 
these were a randomised trial with an untreated control group.(14-16)   However, opposing 
results have also been demonstrated.(17,18)      Potential reasons for this include small, 
heterogeneous, ethnically diverse populations treated with variable chemotherapy regimens 
in both advanced and resectable disease settings, and the addition of other related 
polymorphisms such as the TS 3’UTR 6 base pair polymorphism to analyses.(19)      We 
caveat our discussion with an awareness that length based polymorphism assessment 
resulted in a discordance rate of 4.2% for TS polymorphism status.   However, as our 
findings for the 2R/2R genotype are quite striking, even when a stringent p.value is applied 
to correct for multiplicity,  and were confirmed with repeated simulation testing to account for 
any discrepancy in TS genotype assessment we do not think that this is likely to have unduly 
affected these results.   
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Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in 5-fluorouracil 
catabolism and variation in DPD levels and activity have profound effects of fluoropyrimidine 
metabolism and toxicity.  The most well described of these is a DPYD 2* splice variant 
polymorphism which results in a non-functional enzyme and is associated with 
fluoropyrimidine related toxicity in many studies.(6,20-22)   Although low patient deleterious 
allele frequency and lack of statistical significance due to correction for multiplicity means 
that we cannot be definitive in our conclusions,   our results are consistent with these data.   
However,  we think that these results are of secondary importance to the survival outcomes 
presented.  
We asked two questions from our dataset, firstly, can genotyping be used to differentiate 
between  those who derive a survival benefit from perioperative chemotherapy and those 
who do not, and secondly,  if these genotypes were assessed preoperatively, would it 
possible to predict excessive toxicity prior to commencing chemotherapy?    Regarding 
survival benefit, our findings relating the favourable effects of the TS 2R/2R genotype are 
shared with several other large studies.    Therefore, is further validation with a clinical trial 
required?   One small genotype directed clinical trial clinical trial evaluated FOLFOX 
chemotherapy in 25 patients with TS 2R containing genotypes (2R/2R and 2R/3R) and found 
that radiological response rates did not differ compared to historical control.(33)  However, 
based on our results only the 2R/2R genotype would benefit from this approach; this was 
also suggested in subgroup analysis of that study.     As patients with 3R containing 
genotypes did not appear to benefit from fluoropyrimidine based chemotherapy in MAGIC, 
we suggest that alternative treatment options should be evaluated for these patients.   
Omitting perioperative chemotherapy completely is unlikely to be acceptable as many 
patients (especially those with proximal tumours) require downstaging prior to surgical 
resection.  Alternatively, patients with 3R containing genotypes could be treated with higher 
doses of fluoropyrimidines, although this could be result in increased toxicity.   This 
approach in UGT1A1 genotyped patients has demonstrated that patients who are wildtype or 
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heterozygous for the deleterious *28 allele can tolerate increased doses of irinotecan 
compared to UGT1A1 *28 homozygotes.(34,35)    Finally, a non-fluoropyrimidine containing 
regimen could be considered; for patients with tumours of the gastroesophageal junction or 
oesophagus chemoradiotherapy with carboplatin and paclitaxel would seem a reasonable 
alternative.    
With respect to avoiding toxicity, the relative rarity of alleles which predict for significant 
toxicity such as DPYD 2A* is associated with significant screening costs even when toxicity 
is reduced by the use of pre-emptive dose reductions.(36)   As such, neither the European 
Medicines Agency nor the US Food Drug Administration require testing for DPYD variants 
prior to treatment with fluoropyrimidines despite the availability of advice from expert groups 
such Clinical Pharmacogenetics Implementation Consortium and the Dutch 
Pharmacogenetics Working Group which provide clinical practice guidelines on genotype 
based drug dosing.(37,38)   In the MAGIC trial, the most common grade 3 or greater 
chemotherapy associated toxicity was neutropenia which is likely to be due to epirubicin and 
which is not predicted by any of the polymorphisms which we examined.    Therefore, routine 
testing for DPYD 2A* polymorphisms is unlikely to significantly decrease toxicity in patients 
treated with MAGIC type chemotherapy. 
The interaction between chemotherapy and genotype is complex, and coloured by many 
other clinical variables such as age, ethnicity, gender, hepatorenal function, and the 
interaction between individual components of each chemotherapy regimen.      This has 
profound implications for the accuracy of toxicity or outcome prediction using genotyping.  
One potential flaw relating specifically to this work is that not all MAGIC trial participants 
were included in the current study as not all provided tissue for analysis, therefore we 
caution that the analysis could be underpowered to detect small effect sizes.     On one 
hand, if a patient did not undergo surgery due to failure to respond to treatment then no 
tissue was available for analysis.  Alternatively, patients with excessive toxicity due to 
chemotherapy may also have stopped chemotherapy prior to surgery.  These potential 
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biases may be reflected in the borderline improved overall survival demonstrated for patients 
with polymorphism data available.  Thus although germline genotype will not be altered by 
treatment, any true assessment of the predictive power of genotype would preferentially be 
performed in pre-treatment samples for these reasons.   A second issue relates to the 
technical challenges associated with length based polymorphism assessment; moving 
forward advances in high throughput next generation sequencing technologies should 
ensure improved accuracy and speed of results with decreased DNA requirements.  
In summary, ours is the first study to examine the effect of germline polymorphisms on 
pathological response and survival outcomes for patients treated with perioperative 
chemotherapy for operable oesophagogastric cancer, with a randomised control group.   We 
found that patients with a TS 2R/2R genotype (representing 34% of the population) had 
excellent survival when treated with perioperative ECF chemotherapy.      In contrast, 
patients with a 3R containing genotype did not appear to derive a similar benefit from 
standard dose fluoropyrimidine based chemotherapy when compared to patients treated with 
surgery alone.     It is salutary to note that despite recent progress in our understanding of 
the molecular biology underpinning gastroesophageal cancer that only one targeted drug, 
trastuzumab, is licenced in this disease, and that almost all patients will receive platinum and 
fluoropyrimidine based chemotherapy as a component of their treatment.(39,40)     
Therefore use of available data relating to patient selection for standard of care 
chemotherapy to design a prospective would appear to be a sound choice.    
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Table 1:  Germline polymorphisms analysed 
Gene Polymorphism rsID 
OPRT G638C (Gly213Ala) 1801019 
DPYD IVS14+1G>A DPYD2A 
DPYD A1627G 1801159 
ERCC1 C118T 11615 
ERCC1 C8092A 3212986 
ERCC2 Lys751Gln 13181 
XRCC1 A399G 25487 
GSTP1 I105V 1695 
TS 2R/3R 5'UTR 2R/3R repeat  
GSTT1 deletion   
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Table 2: Frequency of each polymorphism 
  Chemo+Surgery Surgery alone Total 
TS 2R/3R 5'UTR 2R/2R 38 (31%) 53 (36%) 91 (34%) 
 2R/3R 51 (41%) 61 (42%) 112 (41%) 
 3R/3R 35 (28%) 32 (22%) 67 (25%) 
 Total 124 146 270 
     
GSTP1  rs1695 A 74 (56%) 73 (47%) 147 (51%) 
 AG 53 (40%) 67 (43%) 120 (42%) 
 G 6 (5%) 16 (10%) 22 (8%) 
 Total 133 156 289 
     
     
OPRT rs1801019 C 5 (4%) 3 (2%) 8 (3%) 
 G 92 (69%) 92 (59%) 184 (64%) 
 CG 36 (27%) 60 (39%) 96 (33%) 
 Total 133 155 288 
     
DPYD2A IVS14+1G>A G 131 (99%) 152 (100%) 283 (>99%) 
 GA 1 (1%) 0 (0%) 1 (<1%) 
 Total 132 152 284 
     
DPYD rs1801159 A 96 (73%) 100 (65%) 196 (68%) 
 AG 27 (20%) 48 (31%) 75 (26%) 
 G 9 (7%) 7 (5%) 16 (6%) 
 Total 132 155 287 
     
ERCC1 rs11615 C 19 (14%) 29 (19%) 48 (17%) 
 CT 70 (53%) 68 (44%) 138 (48%) 
 T 44 (33%) 57 (37%) 101 (35%) 
 Total 133 154 287 
     
ERCC1 rs3212986 G 61 (46%) 84 (55%) 145 (51%) 
 GT 64 (48%) 60 (39%) 124 (43%) 
 T 7 (5%) 10 (6%) 17 (6%) 
 Total 132 154 286 
     
ERCC2 rs13181 G 23 (17%) 20 (13%) 43 (15%) 
 GT 62 (47%) 63 (41%) 125 (44%) 
 T 48 (36%) 71 (46%) 119 (41%) 
 Total 133 154 287 
     
XRCC1 rs25487 A 19 (14%) 18 (12%) 37 (13%) 
 AG 56 (42%) 67 (44%) 123 (43%) 
 G 57 (43%) 69 (45%) 126 (44%) 
 Total 132 154 286 
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Table 3:   Genotype and pathological response to chemotherapy 
Genotype  TRG 1-2 TRG 3-5 p OR for TRG 
3-5 
95%CI 
TS   
2R/2R 
  
9 (24.3) 28 (75.7) (0.536) 1.0  
2R/3R 8 (16.7) 40 (83.3) 0.384 1.61 0.55-4.68 
3R/3R 5 (14.7) 29 (85.3) 0.313 1.86 0.56-6.25 
      
2R/2R 9 (24.3) 28 (75.7)  1.0  
2R/3R + 
3R/3R 
13 (15.9) 69 (84.2) 0.274 1.71 0.66-4.44 
      
GSTP1 rs1695   
A  11 (15.5) 60 (84.5) (0.812) 1.0  
AG 10 (20.0) 40 (80.0) 0.520 0.73 0.29-1.89 
G 1 (16.7) 5 (83.3) 0.939 0.92 0.10-8.62 
      
OPRT   
C 2 (40.0) 3 (60.0) (0.308) 1.0  
G 16 (18.2) 72 (81.8) 0.249 3.0 0.46-19.5 
GC 4 (11.8) 30 (88.2) 0.128 5.0 0.63-39.7 
      
DPYD rs1801159   
A 14 (15.4) 77 (84.6) (0.413) 1.0  
AG 5 (18.5) 22 (81.5) 0.698 0.80 0.26-2.46 
G 3 (33.3) 6 (66.7) 0.186 0.36 0.08-1.62 
      
ERCC1 rs11615   
C 3 (16.7) 15 (83.3) (0.211) 1.0  
CT 15 (22.7) 51 (77.3) 0.580 0.68 0.17-2.67 
T 4 (9.3) 39 (90.7) 0.417 1.95 0.39-9.77 
      
ERCC1 rs3212986   
G 8 (13.6) 51 (86.4) (0.496) 1.0  
GT 12 (19.7) 49 (80.3) 0.371 0.64 0.24-1.70 
T 2 (28.6) 5 (71.4) 0.308 0.39 0.06-2.38 
      
ERCC2 rs13181   
G 3 (14.3) 18 (85.7) (0.879) 1.0  
GT 11 (19.0) 47 (81.0) 0.631 0.71 0.18-2.85 
T 8 (16.7) 40 (83.3) 0.804 0.83 0.20-3.51 
      
XRCC1 rs25487   
A 2 (11.1) 16 (88.9) (0.752) 1.0  
AG 10 (18.9) 43 (81.1) 0.453 0.54 0.11-2.72 
G 10 (17.9) 46 (82.1) 0.503 0.58 0.11-2.91 
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 Table 4:  Association between TS genotype and overall survival 
(2
nd
 HR & p-value are adjusted for: age, subtype, gender, site of primary, WHO, nodal status) 
 Chemotherapy Surgery alone Overall 
 2R/2R 2R/3R 3R/3R 2R/2R 2R/3R 3R/3R 2R/2R 2R/3R 3R/3R 
Patients 38 
(31%) 
51 
(41%) 
35 
(28%) 
51 
(36%) 
59 
(41%) 
32 
(23%) 
89 
(34%) 
110 
(41%) 
67 
(25%) 
Events 15 36 20 31 38 25 46 74 45 
Median 
survival 
Not 
reached 
1.44 1.60 1.76 1.68 2.09 3.31 1.62 1.84 
Log-rank p-
value 
0.0053 0.7212 0.0326 
Hazard ratio 
1 (REF) 
2.66 
3.06 
2.10 
2.64 
1 
(REF) 
1.03 
1.07 
1.23 
1.45 
1 
(REF) 
1.59 
1.73 
1.53 
1.79 
HR p-value 
 
0.002 
0.001 
0.032 
0.009 
 
0.896 
0.778 
0.448 
0.190 
 
0.013 
0.005 
0.043 
0.008 
          
Combined analysis 
 2R/2R 2R/3R 
+ 
3R/3R 
 2R/2R 2R/3R 
+ 
3R/3R 
 2R/2R 2R/3R 
+ 
3R/3R 
 
Patients 
38 
(31%) 
86 
 
 
51 
(36%) 
91  
89 
(34%) 
177  
Events 15 56  31 63  46 119  
Median 
survival 
Not 
reached 
1.44  1.76 1.84  3.31 1/71  
Log-rank p-
value 
0.002 0.6519 0.009 
Hazard ratio 
1 (REF) 
2.43 
2.89 
 
1 
(REF) 
1.10 
1.15 
 
1 
(REF) 
1.57 
1.75 
 
HR p-value 
 
0.003 
0.001 
  
0.652 
0.531 
  
0.010 
0.002 
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Supplementary Table 1.   Association between genotype and toxicity ≥ G3 
TS 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
TS No Yes No Yes No Yes No Yes No Yes No Yes 
2R/2R  30 7 36 1 36 1 22 14 37 0 36 1 
 
81.1% 
64.8-92.0 
18.9% 
8.0-35.1 
 
97.3% 
85.8-99.9 
 
2.7% 
0.07-14.16 
97.3% 
85.84-99.93 
2.7% 
0.06-14.16 
61.1% 
43.5-76.9 
38.9% 
23.1-56.5 
100% 
90.5-100 
0% 
0.0-9.5 
97.3% 
85.8-99.9 
2.7% 
0.07-14.2 
2R/3R 39 9 46 3 44 4 32 15 47 2 42 6 
 81.3% 
67.4-91.1 
18.8% 
8.9-32.6 
93.9% 
83.1-98.7 
6.1% 
1.28-16.87 
91.7% 
80.02-97.68 
8.3% 
2.32-19.98 
68.1% 
52.9-80.9 
31.9% 
19.1-47.1 
95.9% 
86.0-99.5 
4.1% 
0.5—14.0 
87.5% 
74.8-95.3 
12.5% 
4.7-25.2 
3R/3R 32 3 34 1 35 0 19 13 32 3 34 1 
 
91.4% 
76.9-98.2 
8.6% 
1.8-23.1 
97.1% 
85.1-99.9 
2.9% 
0.07-14.92 
100% 
90.0-100.0 
0% 
0-0.1 
59.4% 
40.6-76.3 
40.6% 
23.7-59.4 
91.4% 
76.9-98.2 
8.6% 
1.8-23.1 
97.1% 
85.1-99.9 
2.9 
0.07-14.9 
 
 p=0.377 p = 0.732 p = 0.186 p = 0.711 p = 0.185 p = 0.188 
2R/2R 30 7 36 1 36 1 22 14 37 0 36 1 
 
81.1% 
64.8-92.0 
18.9% 
8.0-35.1 
97.3% 
85.8-99.9 
 
2.7% 
0.07-14.16 
97.3% 
85.84-99.93 
2.7% 
0.06-14.16 
61.1% 
43.5-76.9 
38.9% 
23.1-56.5 
100.0% 
90.5-100 
0.0% 
0-9.5 
97.3% 
85.8-99.9 
2.7% 
0.06-14.2 
2R/3R/3R/3
R 
71 12 80 4 79 4 51 28 79 5 76 7 
 85.5% 
76.1-92.3 
14.5% 
7.7-23.9 
95.2% 
88.3-98.7 
4.8% 
1.3-11.7 
95.2% 
88.1-98.7 
4.8% 
1.3-11.9 
64.6% 
53.0-75.0 
35.4% 
23.1-56.5 
94.0% 
86.7-98.0 
6.0% 
2.0-13.3 
91.6% 
83.4-96.5 
8.4% 
3.5-16.6 
 p= 0.592 p = 1.0 p = 1.0 p = 0.835 p = 0.322 p = 0.432 
GSTP1 rs1695 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
 No Yes No Yes No Yes No Yes No Yes No yes 
A  59 13 69 3 70 2 44 22 69 3 67 5 
 
81.9% 
71.1-90.0 
18.1% 
10.0-28.9 
 
95.8% 
88.3-99.1 
4.2% 
0.9-11.7 
97.2% 
90.3-99.7 
2.8% 
0.3-9.7 
66.7% 
54.0-77.8 
33.3% 
22.2-46.0 
95.8% 
88.3-99.1 
4.2% 
0.9-11.7 
93.1% 
84.5-97.7 
6.9% 
2.3-15.5 
AG 45 6 50 2 48 3 31 21 48 4 47 4 
 
88.2% 
76.1-95.6 
11.8% 
4.4-23.9 
96.2% 
86.8-99.5 
3.8% 
0.5-13.2 
 
94.1% 
83.8-98.8 
5.9% 
1.2-16.2 
59.6% 
45.1-73.0 
40.4% 
27.0-55.0 
92.3% 
81.5-97.9 
7.7% 
2.1-18.5 
92.2% 
81.1-97.8 
7.8% 
2.2-18.9 
G 5 1 6 0 6 0 79 45 6 0 6 0 
 
83.3% 
35.9-99.6 
16.7% 
0.4-64.1 
100.0% 
54.1-100 
0.0% 
0-45.9 
100.0% 
54.1-100 
0.0% 
0-45.9 
66.7% 
22.3-95.7 
 
33.3% 
4.3-77.7 
 
100.0% 
54.1-100.0 
0.0% 
0.0-45.9 
100.0% 
54.1-100 
 
0.0% 
0.0-45.9 
 p = 0.582 p = 1.0 p = 0.724 p = 0.740 p = 0.609 p = 1.0 
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OPRT 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
 No Yes No Yes No Yes No Yes No Yes No yes 
C 3 2 4 1 5 0 2 3 5 0 4 1 
 60% 
14.7-94.7 
 
40% 
5.3-85.3 
 
80% 
28.4-99.5 
20% 
20.0 
0.5-71.6 
100% 
47.8-100.0 
0% 
0.0-52.18 
40% 
5.3-85.3 
60% 
14.7-94.7 
100% 
47.8-100.0 
0% 
0.0-52.18 
80% 
28.4-99.5 
20% 
0.5-71.6 
GC 30 5 33 2 33 2 24 9 34 1 34 1 
 85.7% 
69.7-95.2 
14.3% 
4.8-30.3 
 
94.3% 
80.8-99.3 
 
5.7 
0.7-19.2 
94.3% 
80.8-99.3 
5.7% 
0.7-19.2 
 
72.7% 
54.5-86.7 
27.3% 
13.3-45.5 
 
97.1% 
85.1-99.9 
2.9% 
0.07-14.92 
 
97.1% 
85.1-99.9 
2.9% 
0.1-14.9 
 
G 76 13 88 2 86 3 53 33 84 6 82 7 
 85.4% 
76.3-92.0 
14.6% 
8.0-23.7 
 
97.8% 
92.2—99.7 
 
2.2% 
0.3-7.8 
96.6% 
90.5-99.3 
3.4% 
0.7-9.5 
61.6% 
50.5-71.9 
38.4% 
28.1-49.5 
93.3% 
86.1-97.5 
6.7% 
2.5-13.9 
 
92.1% 
84.5-96.8 
 
7.9% 
3.2-15.5 
 p = 0.283 p = 0.082 p = 0.690 p = 0.303 p = 0.752 p = 0.237 
DPYD2A  IVS14+1G>A 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
 No Yes No Yes No Yes No Yes No Yes No Yes 
G 108 19 124 4 122 5 79 41 122 6 118 9 
 
85.0% 
77.6-90.7 
15.0% 
9.3-22.4 
 
96.9% 
92.2-99.1 
3.1% 
96.1% 
91.1-98.7 
3.9% 
1.3-8.9 
64.8% 
55.6-73.2 
35.2% 
26.8-44.4 
 
95.3% 
90.1-98.3 
4.7% 
1.7-9.9 
92.9% 
87.0-96.7 
7.1% 
3.3-13.0 
GA 0 1 0 1 1 0 0 1 1 0 1 0 
 
0.0% 
0-97.5 
100.0% 
2.5-1.0 
 
0.0% 
0.0-97.5 
 
100.0% 
2.5-100.0 
100.0% 
2.5-100.0 
0.0% 
0-97.5 
0.0% 
0.0-97.5 
100.0% 
2.5-100.0 
100.0% 
2.5-100.0 
0.0% 
0.0-97.5 
 
100.0% 
2.5-100.0 
0.0% 
0.0-97.5 
 p = 0.156 p = 0.039 p = 1.0 p = 0.358 p = 1.0 p = 1.0 
DPYD rs1801159 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
 No Yes No Yes No Yes No Yes No Yes No Yes 
A 78 15 90 4 91 2 61 28 90 4 87 6 
 
83.9% 
74.8-90.7 
16.1% 
9.3-25.2 
95.7% 
89.5-98.8 
 
4.3% 
1.2-10.5 
97.8% 
92.4-99.7 
2.2% 
0.3-7.6 
68.5% 
57.8-78.0 
31.5% 
22.0-42.2 
95.7% 
89.5-98.8 
4.3% 
1.2-10.5 
93.5% 
86.5-97.6 
6.5% 
2.4-13.5 
AG 23 3 25 1 24 2 13 12 25 1 24 2 
 88.5% 
69.8-97.6 
11.5% 
2.4-30.2 
96.2% 
80.4-99.9 
3.8% 
0.09-19.6 
92.3% 
74.9—99.1 
7.7% 
0.9-25.1 
52.0% 
31.3-72.2 
48.0% 
27.8-68.7 
96.2% 
80.4-99.9 
3.8% 
0.09-19.6 
92.3% 
74.9-99.1 
7.7% 
0.9-25.1 
G 7 2 9 0 123 5 5 4 8 1 119 9 
 77.8% 
40.0-97.2 
22.2% 
2.8-60.0 
100.0% 
66.3-100.0 
0.0% 
0.0-33.6 
96.1% 
51.8-99.7 
3.9% 
0.2-48.2 
55.6% 
21.2-86.3 
44.4% 
13.7-78.8 
88.9% 
51.8-99.7 
11.1% 
0.2-48.2 
88.9% 
51.8-99.7 
11.1% 
0.2-48.2 
 p = 0.698 p = 1.0 p = 0.143 p = 0.264 p = 0.432 p = 0.700 
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ERCC1 rs11615 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
 No Yes No Yes No Yes No Yes No Yes No Yes 
C 16 2 18 1 18 0 10 9 16 3 16 2 
 88.9% 
65.3-98.6 
11.1% 
1.4-34.7 
94.7% 
74.0-99.9 
5.3% 
0.1-26.0 
100.0% 
81.5-100 
0.0% 
0.0-18.5 
52.6% 
28.9-75.6 
47.4% 
24.5-71.1 
84.2% 
60.4-96.6 
15.8% 
3.4-39.6 
88.9% 
65.3-98.6 
11.1% 
1.4-43.7 
CT 57 12 65 4 67 2 46 19 67 2 65 4 
 82.6% 
71.6-90.7 
17.4% 
9.3-28.4 
94.2% 
85.8-98.4 
5.8% 
1.6-14.2 
97.1% 
89.92-99.65 
2.9% 
0.4-10.1 
70.8% 
58.2-81.4 
29.2% 
18.6-41.8 
97.1% 
89.9-99.6 
2.9% 
0.4-10.0 
94.2% 
85.8-98.4 
5.8% 
1.6-14.2 
T 36 6 42 0 39 3 23 17 40 2 39 3 
 
85.7% 
71.5-94.6 
14.3% 
5.4-28.5 
100.0% 
91.6-100.0 
0.0% 
0-8.4 
92.9% 
80.5-98.5 
7.1% 
1.5-19.5 
57.5% 
40.9-73.0 
42.5% 
27.0-59.1 
95.2% 
83.8-99.4 
 
 
4.8 
0.6-16.2 
92.9% 
80.5-98.5 
7.1% 
1.5-19.5 
 p = 0.839 p = 0.282 p = 0.428 p = 0.216 p = 0.101 p = 0.711 
C  16 2 18 1 18 0 10 9 16 3 16 2 
 88.9% 
65.3-98.6 
11.1% 
1.4-34.7 
94.7% 
74.0-99.9 
5.3% 
0.1-26.0 
100.0% 
81.5-100 
0.0% 
0.0-18.5 
52.6% 
28.9-75.6 
47.4% 
24.5-71.1 
84.2% 
60.4-96.6 
15.8% 
3.4-39.6 
88.9% 
65.3-98.6 
11.1% 
1.4-43.7 
CT + T 93 18 107 4 106 5 69 36 107 4 104 7 
 83.8% 16.2% 96.4% 3.6% 95.5% 4.5% 65.7% 34.3% 96.4% 3.6% 93.7% 6.3% 
 p = 0.737 p = 0.552 p = 1.0 p = 0.306 p = 0.064 p = 0.612 
ERCC1 rs3212986 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
G 51 8 59 0 55 4 33 22 57 2 57 2 
 86.4% 
75.0-94.0 
13.6% 
6.0-25.0 
100.0% 
93.9-100 
0.0% 
0.0-6.0 
93.2% 
83.5-98.1 
6.8% 
1.9-16.5 
60.0% 
45.9-73.0 
40.0% 
27.0-54.1 
96.6% 
88.3-99.6 
3.4% 
0.4-11.7 
96.6% 
88.3-99.6 
3.4% 
0.4-11.7 
GT 50 12 58 5 61 1 41 20 59 4 56 6 
 80.6% 
68.6-89.6 
19.4% 
10.4-31.4 
92.1% 
82.4-97.4 
7.9% 
2.6-17.6 
98.4% 
91.3-100.0 
1.6% 
0.04-8.7 
67.2% 
54.0-78.7 
32.8% 
21.3-46.0 
93.7% 
84.5-98.2 
6.3% 
1.8-15.5 
90.3% 
80.1-96.4 
9.7% 
3.6-19.9 
T 7 0 7 0 7 0 5 2 7 0 6 1 
 100.0% 
59.0-100.0 
0.0% 
0.0-41.0 
100.0% 
59.0-100.0 
0.0% 
0.0-41.0 
100.0% 
59.0-100.0 
0.0% 
0.0-41.0 
71.4% 
29.0-96.3 
28.6% 
3.7-71.0 
100.0% 
59.0-100.0 
0.0% 
0.0-41.0 
85.7% 
42.1-99.6 
14.3% 
0.4-57.9 
 p = 0.438 p = 0.094 p = 0.399 p = 0.676 p = 0.773 p = 0.221 
ERCC2 rs13181 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
G 19 4 22 1 22 1 14 8 20 3 23 0 
 82.6% 
61.2-95.0 
17.4% 
5.0-38.8 
95.7% 
78.1-99.9 
4.3% 
0.1-21.9 
95.7% 
78.1-99.9 
4.3% 
0.1-21.9 
63.6% 
40.7-82.8 
36.4% 
17.2-59.3 
87.0% 
66.4-97.2 
13.0% 
2.8-33.6 
100.0% 
85.2-100.0 
0.0% 
0.0-14.8 
GT 50 8 56 3 56 2 38 17 56 3 53 5 
 86.2% 
74.6-93.9 
13.8% 
6.1-25.4 
94.9% 
85.9-98.9 
5.1% 
1.1-14.1 
96.6% 
88.1-99.6 
3.4% 
0.4-11.9 
69.1% 
55.2-80.9 
30.9% 
19.1-44.8 
94.9% 
85.9-98.9 
5.1% 
1.1-14.1 
91.4% 
81.0-97.1 
8.6% 
2.9-19.0 
T 40 8 47 1 46 2 27 20 47 1 44 4 
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 83.3% 
69.8-92.5 
16.7% 
7.5-30.2 
97.9% 
88.9-99.9 
2.1% 
0.1-11.1 
95.8% 
85.7-99.5 
4.2% 
0.5-14.3 
57.4% 
42.2-71.7 
42.6% 
28.3-57.8 
97.9% 
88.9-99.9 
2.1% 
0.1-11.1 
91.7% 
80.0-97.7 
8.3% 
2.3-20.0 
 p = 0.853 p = 0.717 p = 1.0 p = 0.483 p = 0.155 p = 0.433 
XRCC1 rs25487 
 N&V Diarrhoea Stomatitis Granulocytes Haemaglobin Neuro 
 No Yes No Yes No Yes No Yes No Yes No Yes 
A 17 1 18 0 18 0 10 8 17 1 17 1 
 94.4% 
72.7-99.9 
5.6% 
0.1-27.3 
100.0% 
81.5-100.0 
0.0% 
0.0-18.5 
100.0% 
81.5-100.0 
0.0% 
0.0-18.5 
55.6% 
30.8-78.5 
44.4% 
21.5-69.2 
94.4% 
72.7-99.9 
5.6% 
0.1-27.3 
94.4% 
72.7-99.9 
5.6% 
0.1-27.3 
AG 45 10 52 4 51 4 35 19 55 1 49 6 
 81.8% 
69.1-90.9 
18.2% 
9.1-30.9 
92.9% 
82.7-98.0 
7.1% 
2.0-17.3 
92.7% 
82.4-98.0 
7.3% 
2.0-17.6 
64.8% 
50.6-77.3 
35.2% 
22.7-49.4 
98.2% 
90.4-100.0 
1.8% 
0.0-9.6 
89.1% 
77.8-95.9 
10.9% 
4.1-22.2 
G 46 9 54 1 54 1 34 17 51 4 53 2 
 
83.6% 
71.2-92.2 
16.4% 
7.8-28.8 
98.2% 
90.3-100.0 
1.8% 
0.1-9.7 
98.2% 
90.3-100.0 
1.8% 
0.05-9.7 
 
66.7% 
52.1-79.2 
33.3% 
20.8-47.9 
92.7% 
82.4-98.0 
7.3% 
2.0-17.6 
96.4% 
87.5-99.6 
3.6% 
0.3-8.7 
 p = 0.505 p = 0.358 p = 0.359 p = 0.691 p = 0.300 p = 0.367 
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